Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enables selection of robust toxin-resistant cells but with decreased gene expression of insulin secretory function

Pancreas

Volumn 36, Issue 3, 2008, Pages 294-301

  Liu, Hui Kang ^a,b   McCluskey, Jane T ^a   McClenghan, Neville H ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

cell destruction; DNA damage and repair; Insulin secretion; Ninhydrin; Toxin resistance

Indexed keywords

CATALASE; HYDROGEN PEROXIDE; INSULIN; NINHYDRIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENE EXPRESSION; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; CATALASE; CLONE CELLS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 2; HYDROGEN PEROXIDE; INSULIN; INSULIN-SECRETING CELLS; NINHYDRIN; RATS; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

EID: 41149086932     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181530b4     Document Type: Article

References (35)

1. Mandrup-Poulsen T. Beta-cell apoptosis: stimuli and signaling. Diabetes. 2001;50(suppl 1):S58-S63.
2. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev. 1970;22:485-518.
3. Efrat S. Development of engineered pancreatic beta-cell lines for cell therapy of diabetes. Adv Drug Deliv Rev. 1998;33:45-52.
4. Efrat S. Cell-based therapy for insulin-dependent diabetes mellitus. Eur J Endocrinol. 1998;138:129-133.
5. Bloch K, Vardi P. Toxin-based selection of insulin-producing cells with improved defense properties for islet cell transplantation. Diabetes Metab Res Rev. 2005;21:253-261.
6. Chen G, Hohmeier HE, Gasa R, et al. Selection of insulinoma cell lines with resistance to interleukin-1beta- and gamma-interferon-induced cytotoxicity. Diabetes. 2000;49:562-570.
7. Bloch K, Vardi P. Therapeutic differentiation of tumor-derived insulin-producing cells selected for resistance to diabetogenic drugs. Int J Exp Diabetes Res. 2001;1:233-237.
8. Bloch KO, Zemel R, Bloch OV, et al. Streptozotocin and alloxan-based selection improves toxin resistance of insulin-producing RINm cells. Int J Exp Diabetes Res. 2000;1:211-219.
9. Bloch KO, Vorobeychik M, Yavrians K, et al. Selection of insulin-producing rat insulinoma (RINm) cells with improved resistance to oxidative stress. Biochem Pharmacol. 2003;65:1797-1805.
10. Chen G, Hohmeier HE, Newgard CB. Expression of the transcription factor STAT-1 alpha in insulinoma cells protects against cytotoxic effects of multiple cytokines. J Biol Chem. 2001;276:766-772.
11. Lenzen S, Panten U. Alloxan: history and mechanism of action. Diabetologia. 1988;31:337-342.
12. Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep. 1982;66:427-438.
13. McClenaghan NH, Flatt PR. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab. 1999;1:137-150.
14. Jorns A, Munday R, Tiedge M, et al. Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro. J Endocrinol. 1997;155:283-293.
15. Lenzen S, Freytag S, Panten U. Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. Mol Pharmacol. 1988;34:395-400.
16. Lenzen S, Brunig H, Munster W. Effects of alloxan and ninhydrin on mitochondrial Ca2+ transport. Mol Cell Biochem. 1992;118:141-151.
17. Lenzen S, Mirzaie-Petri M. Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose. Naunyn Schmiedebergs Arch Pharmacol. 1992;346:532-536.
18. McKelvey-Martin VJ, Green MH, Schmezer P, et al. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res. 1993;288:47-63.
19. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia. 1981;20:573-577.
20. Murata M, Takahashi A, Saito I, et al. Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol. 1999;57:881-887.
21. Rabinovitch A, Suarez WL, Thomas PD, et al. Cytotoxic effects of cytokines on rat islets: evidence for involvement of free radicals and lipid peroxidation. Diabetologia. 1992;35:409-413.
22. Okamoto H. The role of poly(ADP-ribose) synthetase in the development of insulin-dependent diabetes and islet B-cell regeneration. Biomed Biochim Acta. 1985;44:15-20.
23. Asayama K, Nyfeler F, English D, et al. Alloxan-induced free radical production in isolated cells: selective effect on islet cells. Diabetes. 1984;33:1008-1011.
24. 2 as an intermediate. J Biol Chem. 1991;266:2112-2114.
25. Munday R. Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of Bactive oxygen[ species. Biochem Pharmacol. 1988;37:409-413.
26. Dianov G, Lindahl T. Reconstitution of the DNA base excision-repair pathway. Curr Biol. 1994;4:1069-1076.
27. Satoh MS, Lindahl T. Enzymatic repair of oxidative DNA damage. Cancer Res. 1994;54:1899s-1901s.
28. Chen KH, Yakes FM, Srivastava DK, et al. Up-regulation of base excision repair correlates with enhanced protection against a DNA damaging agent in mouse cell lines. Nucleic Acids Res. 1998;26:2001-2007.
29. Lenzen S, Brand FH, Panten U. Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition. Br J Pharmacol. 1988;95:851-859.
30. Bunnag SC, Warner NE, Bunnag S. Effect of alloxan on the mouse pancreas during and after recovery from diabetes. Diabetes. 1967;16:83-89.
31. Lazarow A. A spontaneous recovery from alloxan diabetes in the rat. Diabetes. 1952;1:363.
32. Rerup C. Spontaneous remission of alloxan diabetes in mice. Diabetologia. 1968;4:312.
33. Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology. 2001;142:4956-4968.
34. Hamamoto Y, Tsuura Y, Fujimoto S, et al. Recovery of function and mass of endogenous beta-cells in streptozotocin-induced diabetic rats treated with islet transplantation. Biochem Biophys Res Commun. 2001;287:104-109.
35. Jorns A, Klempnauer J, Tiedge M, et al. Recovery of pancreatic beta cells in response to long-term normoglycemia after pancreas or islet transplantation in severely streptozotocin diabetic adult rats. Pancreas. 2001;23:186-196.